Diabetes
Conditions
Interventions
experimental group:Lixisenatide combined with insulin glargine
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patients with type 2 diabetes mellitus were definitely diagnosed; 2. Aged >= 18 and = 19kg/m2 4. Premixed insulin (human insulin or insulin analogues, combined with 0 to 3 kinds of oral hypoglycemic drugs) was used to treat patients with a total daily dose of = 1.0 ng / ml; 7. Patients who can monitor their blood glucose and adjust the dose of insulin glargine under the guidance of doctors; 8. Patients who have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with type 1 diabetes mellitus; 2. Patients currently using GLP-1 receptor agonists; 3. Pregnant / lactating women; 4. Patients with serum creatinine >= 1.5mg/dl (133umol / L); 5. Patients with active liver disease, jaundice, or ALT / AST >= 2.5 times of the upper normal limit in screening period; 6. Patients with long-term or repeated use of systemic corticosteroids; 7. Diabetic patients with acute complications; 8. Patients with major concomitant diseases or serious complications; 9. Patients allergic to insulin glargine or any of its components; 10. Patients who are allergic to lisinotide or have contraindications to use lisinotide; 11. Patients who have participated in any other clinical research project within 3 months.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| FPG;PBG;weight; | — |
Primary
| Measure | Time frame |
|---|---|
| GHbA1c; | — |
Countries
China
Contacts
Public ContactJunqing Zhang
Peking University First Hospital
Outcome results
None listed